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Abstract 
Pharmaceuticals have played an important role in improving the quality of life of the human 
population in modern times. However, it must also be acknowledged that both the 
production and use of pharmaceuticals have a significant, negative impact on the 
environment and consequently, a negative impact on the health of humans and wildlife. 
This negative impact is due to the embedded carbon in pharmaceuticals’ manufacture and 
distribution and the waste generated in their manufacture, consumption and disposal. 
Pharmaceutical waste is comprised of contaminated waste (unwanted pharmaceuticals and 
their original containers) and non-contaminated waste (non-hazardous packaging waste).  
Pharmacists, with their professional commitment to the quality use of medicines and their 
active participation in the medicines management pathway, already play an important role 
in the more sustainable use of pharmaceuticals. Even so, they have the potential to play an 
even greater role with the environmentally responsible disposal of pharmaceutical waste 
(including packaging waste) and the education of other health professionals and the general 
public on this topic. 
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Introduction 
Pharmaceuticals have played an important role in improving the quality of life of the 
human population in modern times (e.g. pharmaceuticals such as penicillin, insulin, 
smallpox and polio vaccines, aspirin, morphine, oral contraceptives and digoxin). Whilst 
acknowledging the importance of the role of pharmaceuticals in improving many ‘quality of 
life’ markers in the domains of human physical, mental and social wellbeing, it must also be 
acknowledged that pharmaceuticals and their packaging have a significant negative impact 
on the environment. This negative impact is due to the embedded carbon in 
pharmaceuticals’ manufacture and distribution and through the waste generated in their 
manufacture, consumption and disposal (Gell, 2010). There are both negative impacts on 
the health of humans (Blashki et al., 2011; Costello et al., 2009; Intergovernmental Panel on 
Climate Change, 2007) and on the health of wildlife (Arnold et al., 2013; Jobling, Nolan, 
Tyler, Brighty, & Sumpter, 1998; Jones, Voulvoulis, & Lester, 2003). Despite the evidence in 
the literature highlighting the negative impacts of pharmaceuticals on the health of humans 
and wildlife, there is very little research reported in international and national pharmacy or 
medical literature on pharmacists’ attitudes and behaviours regarding the environmentally 
responsible handling of pharmaceutical waste. In this paper, the authors argue that 
pharmacists could and should play a major role in minimising the negative impact of 
pharmaceutical waste on the environment.  
 
The Negative Impact of Pharmaceuticals on the Environment 
The negative impact of pharmaceuticals on the environment originates from three 
sources (Kummerer & Hempel, 2010). These are the carbon footprint of pharmaceuticals 
through the embedded carbon in their manufacture and distribution and the incineration of 
unwanted pharmaceuticals and original containers, the chemical effects of the 
pharmaceuticals themselves and their packaging waste. Each of these will now be examined 
in turn. The first source of environmental impact of pharmaceuticals is through the carbon 
footprint. The size of the carbon footprint of pharmaceuticals in the public hospital sector is 
significant. For example, in the NHS England pharmaceuticals comprised 22% of the total 
carbon footprint in 2010, equating to 4.4 million tonnes of CO2 emissions, which in turn 
comprises 3% of the UK’s total carbon footprint (NHS Sustainable Development Unit, 2012). 
The second source of environmental impact due to pharmaceuticals, as described by 
Kummerer and Hempel (2010), is the direct chemical impact on the environment of the 
pharmaceuticals themselves. The issue of pharmaceuticals in the environment has been of 
growing concern both amongst the public and the scientific community for over two 
decades (Bound, Kitsou, & Voulvoulis, 2006; Calisto & Esteves, 2009; da Graca Martinho & 
Martins dos Santos, 2011; Eissen & Backhaus, 2011; Jobling et al., 1998; Kümmerer, 2010; 
Mompelat, Le Bot, & Thomas, 2009; Ternes, 1998; Vallini & Townend, 2010). Over the last 
decade there has been an increasing body of published research on this topic (Arnold et al., 
2013). Even though pharmaceuticals appear in very low concentrations in the environment 
and thus would appear to pose a negligible risk to humans (Cunningham, Binks, & Olson, 
2009; Fent, Weston, & Caminada, 2006; Sherer, 2006) they have the potential to exert a 
cumulative effect on humans (Ruhoy & Daughton, 2008), a negative effect on human 
foetuses (Koshy, 2013) and a significant negative impact on wildlife. For example, exposure 
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to the pharmaceutical diclofenac has resulted in the virtual extinction of vultures in Asia 
(Arnold et al., 2013; Oaks et al., 2004; Ogada, Keesing, & Virani, 2012; Sumpter, 2010; Swan 
et al., 2006). Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) and is readily 
available over the counter of pharmacies without a doctor’s prescription. Veterinary use of 
this widely-available NSAID has resulted in the virtual extinction of three vulture species to 
the most severe category of global extinction risk (Swan et al., 2006). Vultures in Asia have 
been exposed to diclofenac when scavenging on dead livestock that were treated with 
diclofenac shortly before death (Oaks et al., 2004; Swan et al., 2006). Exposure leads to 
renal damage, gout, acute renal failure and death (Swan et al., 2006).  
 
Pharmaceuticals enter the environment via a number of pathways but mostly from 
patient excretion or the disposal of unwanted pharmaceuticals. The size of the issue is 
brought into context when one considers that the global pharmaceuticals market is worth 
US$300 billion a year, a figure expected to rise to US$400 billion within three years (World 
Health Organisation, 2013). Of these pharmaceuticals, up to 90% of each administered dose 
may be excreted unchanged with the potential for metabolites to be converted back to 
active compound by the action of bacteria during the sewerage treatment process (Jones, 
Voulvoulis, & Lester, 2001). This transformation during the sewerage treatment process may 
alter the physical and chemical properties of the pharmaceutical and determine whether it 
will partition into the sludge or liquid phase of the sewerage treatment process (Jones et al., 
2001; Ternes, 1998). Unfortunately, sewerage treatment plants fail to remove a significant 
portion of these active compounds from either the liquid or the sludge phases (Fisher & 
Borland, 2003; Jones et al., 2001; Joss et al., 2006) resulting in large amounts of 
pharmaceuticals entering the environment. Pharmaceuticals leaving sewerage treatment 
plants can end up in water for agricultural and landscape re-use and potentially in recycled 
drinking water for human and animal consumption. Pharmaceuticals may also be retained 
as active compounds in the sludge phase with entry points into soil, groundwater and 
drinking water. The disposal of pharmaceutical waste, either by incineration or into landfill, 
or disposal down sinks or toilets that ends up in the sewerage system, creates entry points 
into the atmosphere or into ground water that may potentially enter drinking water. 
Through entry into drinking water there is the potential for pharmaceuticals to affect both 
the health of aquatic organisms as Jobling et al’s (1998) research demonstrated and the 
health of humans.  
 
The third source of environmental impact due to pharmaceuticals, as described by 
Kummerer and Hempel (2010), is due to pharmaceuticals’ packaging waste. Pharmaceutical 
packaging waste is comprised of several components – the original container (the bottle, 
box or vial that contains or contained the pharmaceutical), cardboard outers, paper from 
consumer information leaflets and/or product information for health professionals, shrink 
wrap, foil strips for individual oral dose formulations, cartons and wooden pallets. 
Pharmaceutical waste may be separated into contaminated waste (unused pharmaceuticals 
and their original containers) and non-contaminated waste (packaging materials). WHO 
classifies unwanted pharmaceuticals and their original containers as contaminated waste 
requiring high temperature incineration to minimize the risk of pharmaceuticals entering 
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the natural environment (World Health Organisation, 2011). Non-contaminated 
pharmaceutical packaging waste is classified as non-hazardous, general waste that may be 
recyclable or compostable (World Health Organisation, 2011). Pharmaceutical packaging 
differs substantially from food packaging. It requires scientific and engineering expertise to 
ensure pharmaceuticals do not leach out of their original containers in transit and arrive at 
their destination with efficacy unchanged. The packaging must ensure that the 
pharmaceutical’s stability, sterility and purity remains uncompromised (Bauer, 2009). 
Pharmaceutical packaging must also be made of materials that will not themselves 
chemically react with the pharmaceutical, will provide thermal protection, and will prevent 
moisture and oxygen coming into contact with the pharmaceutical and reacting with it 
(Bauer, 2009). With increasing pressure being applied by stakeholders to the pharmaceutical 
sector to become more environmentally responsible (Leaver, 2008), pharmaceutical 
packaging materials are beginning to change (Bauer, 2009). Traditional pharmaceutical 
packaging materials such as glass, metal and older plastics such as polyvinyl chloride (PVC) 
are being replaced with newer and more efficient materials such as crystalline and 
biologically derived plastics (Bauer, 2009). Innovation in this area is vital as the older plastics 
used in pharmaceutical packaging have a high volume-to-weight ratio and contribute 
significantly to landfill (Bauer, 2009). Wooden pallets are also a problem in some cases with 
companies not being allowed to recycle them due to concerns about the wooden fibres 
affecting the quality of the product (Leaver, 2008). With space for landfill now becoming a 
concern in many countries (Bauer, 2009; Singh, Sharma, & Malviya, 2011), reducing landfill 
through the recycling of pharmaceutical packaging waste potentially has important 
implications for the environment and for hospitals in reducing their waste removal costs. In 
Australia, manufacturers and suppliers are encouraged to reduce the amount of packaging 
waste or move to more ecofriendly packaging materials to reduce the environmental impact 
of packaging materials across all industries. In 1999, the National Packaging Covenant (name 
changed to Australian Packaging Covenant (APC) in 2010) was launched with the aim of 
changing the culture of business to design more sustainable packaging, increase recycling 
rates and reduce packaging litter. The APC is an agreement between government, industry 
and community groups to address packaging sustainability issues (Australian Packaging 
Covenant, 2013a). The APC aims to reduce the environmental impact of consumer 
packaging by encouraging the design of packaging that is more resource efficient and more 
recyclable and increasing the recovery and recycling of used packaging (Allan & A'Vard, 
2013). To encourage companies to sign up to the APC, Australian State governments require 
that companies with an annual turnover greater than $5 million either sign the APC or 
comply with the ‘National Environmental Protection Measure (Used Packaging Materials) 
2011’ (Australian Packaging Covenant, 2013a). Many pharmaceutical manufacturers and 
suppliers with offices in Australia are signatories to the APC but some of the largest 
suppliers of generic pharmaceuticals into Australia are based in India and they are not 
signatories (Australian Packaging Covenant, 2013b). Minimising the impact of 
pharmaceuticals on the environment lies with maximising resource efficiency to reduce the 
actual amount of waste produced and ensuring the most environmentally responsible 
disposal of this pharmaceutical waste. These two options will now be discussed.  
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Maximising Resource Efficiency 
Globally, it is estimated that less than half of all patients are treated in compliance with 
medical guidelines and more than half of all patients fail to take their medicines as 
prescribed or dispensed (Holloway, 2011). Non-adherence is a global issue with non-
adherent rates of approximately 50% amongst patients with chronic disease in developed 
countries and even higher in developing countries (World Health Organisation, 2003). Such 
inappropriate use is not only an inefficient use of resources and hence wasteful, but it also 
“causes patient harm in terms of lack of satisfactory outcome, serious adverse events and 
increased antimicrobial resistance” (Holloway, 2011) p. 335.  The efficient use of 
pharmaceuticals is referred to by the World Health Organisation (WHO) (1985) as the 
rational use of medicines which occurs “when patients receive the appropriate medicines, in 
doses that meet their own individual requirements, for an adequate period of time and at 
the lowest cost, both to them and the community” (Holloway, 2011) p. 335. The challenge 
of resource efficiency was first responded to in Australia through the Pharmaceutical 
Benefits Scheme (PBS), introduced in 1950 to ensure equity of access to safe and affordable 
medicines for all Australians (Hunt, 2010). Then it was further addressed through the 
National Medicines Policy (NMP) introduced in 2000 with one of its central objectives being 
the Quality Use of Medicines. The Quality Use of Medicines argues for the judicious, 
appropriate, safe and efficacious use of medicines (Australian Government, 2000). 
Ultimately, it was the economic cost to the Australian Government of the burgeoning PBS 
that was the key driver for the development of a National Medicines Policy (Hunt, 2010) and 
it continues to be the main driver of resource efficiency (Treasury, 2010) p.49. 
Environmental considerations are not a driver but rather, a co-benefit, of cost-driven 
resource efficiency and patient safety measures in Australia.  
 
Disposal of Pharmaceutical Waste 
 The disposal of pharmaceutical waste refers to the disposal of unwanted 
pharmaceuticals and pharmaceuticals’ packaging. Unwanted pharmaceuticals include 
expired, unused and contaminated pharmaceuticals (Koshy, 2013; Taylor, 2010) all of which 
cannot be reused and require disposal. Factors contributing to the accumulation of 
unwanted pharmaceuticals include changes in dose, death of patient, non-adherence to 
therapy or non-completion of course of therapy (e.g. antibiotics or analgesics) and 
discontinuation of treatment due to unpleasant side effects (Daughton & Ruhoy, 2008; 
Koshy, 2013; Taylor, 2010; Vollmer, 2010).  Over-prescribing of pharmaceuticals by doctors 
is also a contributor to excess unwanted pharmaceuticals (Ekedahl, 2006). The role of 
pharmacists through the Quality Use of Medicines, as described earlier, and as set down in 
the ‘Consensus Statements’ (International Pharmaceutical Federation (FIP), 2008) aims to 
reduce the amount of unwanted pharmaceuticals in the community. Globally, there is much 
confusion as to the most appropriate means of disposing of unwanted pharmaceuticals 
(Tong, Peake, & Braund, 2011). A review of the literature on the disposal of unwanted 
pharmaceuticals by the public found that the most popular methods were in the household 
garbage or tipped down the toilet or sink (Tong et al., 2011). Liquid formulations were more 
likely to be disposed of down the sink or toilet whilst solid formulations were more likely to 
be disposed of in the garbage (Braund, Peake, & Shieffelbien, 2009; Gotz & Deffner, 2010; 
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Kotchen, Kallaos, Wheeler, Wong, & Zahller, 2009; Tong et al., 2011). All of these methods 
have a negative impact on the natural environment (Braund et al., 2009; Daughton & Ruhoy, 
2009; Vollmer, 2010). Even though WHO has provided best practice guidelines 
recommending high temperature incineration for contaminated pharmaceutical waste 
(World Health Organisation, 2011) there is still confusion as to how to dispose of 
pharmaceuticals. Another issue is access by the public to high temperature incineration 
facilities. High temperature incineration is available to hospitals in many countries through 
contracts with private waste management firms. However, community access to such 
means of disposal for household pharmaceutical waste is problematic leading to disposal 
that allows pharmaceuticals to enter the environment. In Australia, the public are 
encouraged to return unwanted medicines to their local community pharmacy for disposal 
as part of the Return of Unwanted Medicines (RUM) project (2011). These returned 
medicines are collected free of charge from each participating community pharmacy and 
taken to a central location for incineration. Currently in either community or hospital 
pharmacy settings in Australia, non-contaminated packaging waste is not separated out 
from the contaminated waste with returned unwanted pharmaceuticals – both 
contaminated and non-contaminated waste are incinerated adding to greenhouse gas 
emissions. During the dispensing of new prescriptions, any unrequired packaging waste 
tends to go into general waste bins destined for landfill.  
 
The Role of Pharmacists 
Pharmacists have a potential role to play in minimising the impact of pharmaceuticals on 
the environment both through maximising resource efficiency to reduce the actual amount 
of waste produced and ensuring the most environmentally responsible disposal of this 
pharmaceutical waste. Much research has already been conducted worldwide in the area of 
pharmacists’ contributions to the efficient use of medicines (the quality use of medicines) 
including research in the area of patient adherence (Vermeire, Hearnshaw, Van Royen, & 
Denekens, 2001) and preventative health strategies to reduce the amount of 
pharmaceuticals dispensed (Daughton & Ruhoy, 2010).  The development of the medicines 
management pathway which describes the cognitive and physical steps and processes in the 
use of medicines (Stowasser, Allinson, & O'Leary, 2004) highlighted the areas where 
pharmacists could influence the quality use of medicines i.e. the judicious, appropriate, safe 
and efficacious use of medicines.   The importance of the role of pharmacists in the efficient 
use of medicines is acknowledged in published literature (Graudins, 2004; Smith, 2012; Tan, 
Stewart, Elliott, & George, 2012). This body of literature includes the important role played 
by hospital pharmacists (Abdel-Qader, Harper, Cantrill, & Tully, 2010; Claus, Barbara, Fien, & 
Hugo, 2012; Gardner & Graner, 2009; Haavik et al., 2011; Raman-Wilms, 2010; Torelli, Reis, 
Scopel, Correr, & Andrzejevski, 2013). With regards to the role that pharmacists can play in 
ensuring the most environmentally responsible disposal of pharmaceutical waste, more 
research is needed in this area. There has been much research in the last twenty years on 
the presence of pharmaceuticals in the environment, the impact of pharmaceutical waste 
and the disposal of medicines in the community. However, there has been very little 
research into the attitudes and behaviours of pharmacists regarding the disposal of 
pharmaceutical waste. There have been calls for research into the disposal of unused 
pharmaceuticals (Daughton & Ruhoy, 2008; Koshy, 2013; Tong et al., 2011) and for research 
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into the attitudes of pharmacists regarding the disposal of unwanted pharmaceuticals and 
their knowledge regarding the most appropriate methods for doing so (Koshy, 2013).  
 
Pharmacists can play a very important role in encouraging the environmentally 
responsible handling of pharmaceutical waste. In Australia this role may be of greater 
importance in the hospital pharmacy context compared with the community pharmacy 
context for two reasons. First, pharmacists exert a wider sphere of influence over 
medication usage and disposal in the hospital pharmacy context compared with the 
community pharmacy context (International Pharmaceutical Federation (FIP), 2008). In the 
hospital pharmacy context, pharmacists not only dispense medicines directly to patients but 
they also play a wholesaler function in supplying other departments in the hospital with 
pharmaceuticals. The hospital pharmacy department supplies outlying clinics such as 
oncology and renal medicine, the operating theatres and medical imaging with 
pharmaceuticals used in their clinical practices as well as directly supplying pharmaceuticals 
to patients on prescriptions. This dual role (wholesaler and dispensing) means that hospital 
pharmacists exert a wide sphere of influence over the use of pharmaceuticals in the hospital 
setting. This sphere of influence is articulated in the ‘Consensus Statements’ agreed upon at 
the International Federation of Pharmacists’ (FIP) 2008 conference (International 
Pharmaceutical Federation (FIP), 2008). The overarching statements call for hospital 
pharmacists to be involved in all steps in the supply of medicines1 within a hospital and that 
the Chief Pharmacist/Director of Pharmacy should be the senior professional responsible for 
coordinating the judicious, safe, efficacious, appropriate and cost-effective use of medicines 
in the hospital. Hospital pharmacists should be responsible for all medicines’ logistics within 
the hospital setting and should serve as a resource for all information concerning medicines, 
providing education to other health professionals regarding best practices for medicines 
use. Spheres of influence articulated in these statements as themes include procurement, 
prescribing (hospital pharmacists should have a key role in educating prescribers on the 
access to and evidence for optimal and appropriate use of medicines), and the packaging, 
labelling and storage of medicines throughout the hospital (International Pharmaceutical 
Federation (FIP), 2008). Thus it can be seen that the sphere of influence of hospital 
pharmacists extends beyond the confines of the hospital pharmacy department. The second 
reason why hospital pharmacists working in Australia may play a greater role compared with 
community pharmacists is because a greater volume of pharmaceuticals is handled in 
hospitals compared with the community (Australian Institute of Health and Welfare, 2012). 
By identifying the enablers and barriers to the environmentally responsible handling of 
pharmaceutical waste by hospital pharmacists and pharmacy technicians there is the 
potential for flow-on effects around the hospital. These are twofold.  There is the potential 
for a reduction in the actual amount of pharmaceutical waste produced and for more 
environmentally responsible handling of the pharmaceutical waste that is produced. The 
potential role that hospital pharmacists can play in reducing the environmental impact of 
pharmaceuticals has been identified as an area requiring research (Koshy, 2013). A recent 
study conducted in Kuwait (Abahussain, Waheedi, & Koshy, 2012) examined the practices, 
awareness and opinions of hospital pharmacists working in government hospitals regarding 
                                                        
1
The term ‘medicines’ in these statements may be used interchangeably with the term ‘pharmaceuticals’ used 
elsewhere in this document. 
 8 
the disposal of unwanted pharmaceuticals. The findings would appear to support this call 
for further research. It was found that although the pharmacists were aware of the harmful 
impact of the improper disposal of unwanted pharmaceuticals, their disposal practices were 
suboptimal (Abahassain, Waheedi, & Koshy, 2012). Other researchers have also drawn 
attention to the contribution of hospitals to the environmental impact of pharmaceuticals 
(Escher et al., 2011; Le Corre et al., 2012; Lin & Tsai, 2009; Thomas & Langford, 2010). There 
have been calls for greater awareness of this issue on the part of health professionals and 
for health sector reform to minimize this environmental impact (Fisher, Smith, & Collignon, 
2013).  
 
Conclusion and Implications 
Pharmacists, with their professional commitment to the quality use of medicines and 
their active participation in the medicines management pathway, already play an important 
role in the more sustainable use of pharmaceuticals. Even so, they have the potential to play 
an even greater role with the environmentally responsible disposal of pharmaceutical waste 
and the education of other health professionals and the general public on this topic. At a 
national level, the implementation and active promotion of community pharmacy initiatives 
such as Australia’s Return of Unwanted Medicines (RUM) project, which encourage the 
public to return unwanted medicines to pharmacies for correct disposal will minimise the 
negative impact of pharmaceuticals on the environment. Also, health care organisations 
need to show leadership by encouraging pharmacists and other medical staff both in the 
hospital and community pharmacy settings to separate out non-contaminated packaging 
waste from contaminated waste. There will be less waste incinerated thereby reducing the 
carbon footprint and hospital waste management costs and if pharmacists are able to 
recycle or shred the packaging waste for composting, less waste ending up in landfill.  
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